Humanigen, Inc.

176 articles with Humanigen, Inc.

• Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19

  1/10/2021

  Humanigen, Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S.

• Humanigen Secures U.S. Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T Cell Therapy

  12/28/2020

  Humanigen, Inc . (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the United States Patent and Trademark Office has issued a patent to the Company for the use of lenzilumab in prevention or treatment of cytokine storm and neurotoxicity in patients u

• Humanigen Announces Completion of Enrollment in Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme

  12/17/2020

  Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases, today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM).

• Humanigen to Present at Upcoming Investor Conferences - Dec 14, 2020

  12/14/2020

  Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, announced that the Company’s management will present at the PNC Bank & Solebury Trout COVID Webinar and LD Micro Investor Conference on December 15, 2020.

• Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans

  11/23/2020

  New Humanigen entity in Australia creates focused opportunity for partnering, regional clinical trials and market access

• Humanigen Announces Lenzilumab in COVID-19 Program Updates

  10/2/2020

  Humanigen, Inc. announced updates on its lenzilumab in COVID-19 development program, including written guidance received from the US Food and Drug Administration following a Type B meeting to obtain feedback on plans for an Emergency Use Authorization.

• Humanigen Announces COVID-19 Case Report Demonstrating Rapid Resolution and Discharge after Single IND Emergency Use Authorization of Lenzilumab™

  10/2/2020

  Case report demonstrated rapid resolution of hypoxemia and mobility and potential benefit of lenzilumab beyond the initial acute hyper-inflammatory window After 13 weeks of hospitalization, administration of lenzilumab resulted in rapid improvement in oxygenation and subsequent discharge BURLINGAME, Calif.--( BUSINESS WIRE )-- Humanigen, Inc. , (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused o

• Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab

  9/23/2020

  Humanigen, Inc. announced a strategic collaboration with Thermo Fisher Scientific, a world leader in serving science, to expand the manufacturing capacity for lenzilumab, currently in a Phase 3 registration study in patients with COVID-19, to support a potential Emergency Use Authorization.

• 

  Biopharma Update on the Novel Coronavirus: September 23

  9/23/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.

• Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  9/22/2020

  Management presentation Wednesday, September 23 at 10:50 a.m. EDT

• Humanigen Announces Closing of Public Offering of Common Stock - Sep 22, 2020

  9/22/2020

  Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab™, announced that it has completed its previously announced underwritten public offering of common stock.

• Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on Nasdaq

  9/15/2020

  Humanigen, Inc. (HGEND) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab, today announced that it has commenced an underwritten public offering of 8,000,000 shares of common stock. J.P. Morgan and Jefferies are acting as joint book-running managers for the offering. Humanigen expects

• Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab

  9/15/2020

  In an effort to change the course of this pandemic, advancing lead COVID-19 therapeutics requires matched supply chain efforts and expertise to meet the continued and urgent patient needs.

• Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board     

  9/14/2020

  Independent data safety monitoring board (DSMB) unanimously recommends trial continuation without modification after conducting pre-specified interim analysis for safety, futility, sample size and power

• Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board

  9/14/2020

  Independent data safety monitoring board (DSMB) unanimously recommends trial continuation without modification after conducting pre-specified interim analysis for safety, futility, sample size and power

• Humanigen Announces One-for-Five Reverse Stock Split

  9/4/2020

  Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, announced that its board of directors has determined to effect a 1-for-5 reverse split of its outstanding shares of common stock.

• Humanigen Announces One-for-Five Reverse Stock Split; Reverse Split Facilitates Potential Uplisting to Nasdaq

  9/4/2020

  Humanigen, Inc. announced that its board of directors has determined to effect a 1-for-5 reverse split of its outstanding shares of common stock.

• Humanigen to Present at Upcoming Investor Conferences

  9/2/2020

  Humanigen, Inc., (HGEN) (“Humanigen”), announced today that Cameron Durrant, MD, MBA, Chief Executive Officer, Dale Chappell, MD, MBA, Chief Scientific Officer, and Timothy Morris, Chief Operating and Financial Officer of Humanigen will present company overviews and business updates at the following upcoming investor conferences: LD Micro 500 Conference at 2:20 p.m. on Thursday, September 3, 2020 Bair

• Humanigen to Host Investor KOL Conference Call

  9/1/2020

  Humanigen, Inc., (HGEN) (“Humanigen”), announced today that the Company will host an investor call and webcast to discuss the case-control lenzilumab data in COVID-19 patients published this week in Mayo Clinic Proceedings, including a discussion with the infectious disease expert and lead author of the study

• Lenzilumab COVID-19 Case-Control Study Published in Mayo Clinic Journal

  9/1/2020

  80% reduction in relative risk of invasive mechanical ventilation and/or death in patients treated with lenzilumab compared to the control group Median time to resolution of acute respiratory distress syndrome (ARDS) reduced to one day for patients treated with lenzilumab versus eight days in control group Lenzilumab patients discharged from the hospital in less than half the time compared with control group BURLINGAME, Cali